Strug­gling Io­n­is li­cens­es Bi­cy­cle Ther­a­peu­tic­s' plat­form in a bid to de­vel­op drugs that can cross blood-brain bar­ri­er

At­tempt­ing to re­bound from set­backs ear­li­er this year, Io­n­is has en­list­ed a new part­ner in a quest to cre­ate drugs that can cross the blood-brain bar­ri­er. And the tech­nol­o­gy comes from a British biotech pri­mar­i­ly known for its ef­forts in­to on­col­o­gy.

The col­lab­o­ra­tion will see Io­n­is ex­clu­sive­ly li­cense a plat­form from Bi­cy­cle Ther­a­peu­tics to de­vel­op oligonu­cleotides tar­get­ing the trans­fer­rin re­cep­tor 1, the com­pa­nies an­nounced Tues­day morn­ing. Bi­cy­cle is nab­bing $45 mil­lion up­front and an $11 mil­lion eq­ui­ty in­vest­ment from Io­n­is.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN